Wechselwirkungen · Capecitabine Teva
Capecitabine Teva 150 mg film-coated tablets Capecitabine Teva 500 mg film-coated tablets · Abschnitt 4.5 · PDF-Seite 10
HOS-215396 · Präparat HOS-155434
Brivudine A clinically significant interaction between brivudine and fluoropyrimidines (e.g. capecitabine, 5-fluorouracil, tegafur), resulting from the inhibition of dihydropyrimidine dehydrogenase by brivudine, has been described. This interaction, which leads to increased fluoropyrimidine toxicity, is potentially fatal. Therefore, brivudine must not be administered concomitantly with capecitabine (see section 4.3 and 4.4). There must be at least a 4-week waiting period between end of treatment with brivudine and start of capecitabine therapy. Treatment with brivudine can be started 24 hours after the last dose of capecitabine.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
RxNorm-Namen im Text (wörtliche Treffer, Rolle nicht bewertet): brivudine (HOS-091415) tegafur (HOS-091419) fluorouracil (HOS-086023)
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-07-11T15:40:00Z · SHA-256 360b33238effee7033c9ecfa3731a36e172b67d4837e971f09a6e80d5cda73df · Passage ee73b8989869c4f302b64cf743d8915f9eec894d71de29730de869e788717f3f · Zeichen 100–736 im Abschnitt